Ramelet 1982.

Study characteristics
Methods	Trial design: randomised, double‐blind, study Trial registration number: not reported Country: Switzerland Outpatient or hospital, date trial conducted: not reported Duration of trial participation: 14 days Inclusion criteria: · Clearly defined resistant (defined as being present for over a year) AD · Male or female · Erythema, induration and scaling needed to be present and each sign had to be at least moderately severe. Exclusion criteria: not reported Additional design details: study included both AD and psoriasis patients. Results presented only for AD patients
Participants	Total number randomised: 12 participants (6 to apply the intervention and 6 to apply the comparator) Age: intervention group, mean 33 years, range 18 to 71; comparator group, mean 26 years, range 18 to 56 Sex: intervention group, male n = 3, female n = 3; comparator group, male n = 4, female n = 2 Ethnicity: not reported Duration of eczema: intervention group, mean 11 years, range 3 to 30 years; control group, mean duration 21 years, range 5 to 51 Severity of eczema body site: not reported Number of withdrawals: one participant withdrew from the comparator group because of treatment failure. No withdrawals from the other group Notes: AD was exacerbating in all patients.
Interventions	Run‐in details: not reported Intervention: betamethasone dipropionate 0.05% ointment used twice daily for 14 days · Concurrent treatment: not reported · Other key information: brand: Diprolene Comparator: diflucortolone 0.3% ointment used twice daily for 14 days · Concurrent treatment: not reported · Other key information: brand: Neriforte Concurrent treatments received alongside both intervention and comparator: not reported Notes: none
Outcomes	· Erythema, induration, scaling · Overall therapeutic efficacy · Tolerance and safety
Notes	Funding source: not reported Declarations of interest: not declared Original language of publication: English Other: none